Study guide

9.4 Method Evaluation, Diagnostic Statistics & Point-of-Care Testing

ASCP Hematology Technologist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Hematopoiesis & Cellular Physiology

1.1 Hematopoiesis, Bone Marrow Microenvironment & Growth Factors 1.2 Erythrocyte Physiology, Metabolism & Destruction Pathways 1.3 Leukocyte Kinetics, Morphology & Phagocytic Function 1.4 Platelet Physiology, Ultrastructure & Thrombopoiesis

2 Chapter 2: Erythrocyte Disorders & Non-Hemolytic Anemias

2.1 Iron Metabolism & Iron Deficiency Anemia 2.2 Anemia of Chronic Inflammation, Sideroblastic Anemias & Lead Toxicity 2.3 Hemoglobinopathies & Qualitative Globin Chain Defects 2.4 Alpha and Beta Thalassemias 2.5 Megaloblastic, Macrocytic & Hypoproliferative Anemias

3 Chapter 3: Hemolytic Anemias & Erythrocytosis

3.1 Intrinsic Hemolytic Anemias: Membrane & Metabolic Defects 3.2 Immune-Mediated Hemolytic Anemias & Paroxysmal Nocturnal Hemoglobinuria 3.3 Non-Immune Extrinsic Hemolytic Anemias & Microangiopathies 3.4 Polycythemia & Erythrocytosis Classification

4 Chapter 4: Benign Leukocyte Alterations, Acute Leukemias & Bone Marrow Evaluation

4.1 Quantitative Leukocyte Alterations, Toxic Change & Leukemoid Reaction 4.2 Inherited Leukocyte Anomalies, Reactive Lymphocytosis & Storage Disorders 4.3 Acute Myeloid Leukemia (AML) & Related Neoplasms 4.4 Acute Lymphoblastic Leukemia (ALL) & Precursor Lymphoid Neoplasms 4.5 Bone Marrow Examination, Differential & M:E Ratio Assessment

5 Chapter 5: Chronic Myeloid Neoplasms, MDS & Mature Lymphoid Neoplasms

5.1 Myelodysplastic Syndromes (MDS) & Overlap Syndromes 5.2 Chronic Myeloproliferative Neoplasms (CML, PV, ET, PMF) 5.3 Chronic Lymphocytic Leukemia & Indolent B-Cell Lymphomas 5.4 Aggressive Lymphomas, Hodgkin Lymphoma & Mature T-Cell Disorders 5.5 Plasma Cell Neoplasms & Monoclonal Gammopathies

6 Chapter 6: Hemostasis: Primary, Secondary & Fibrinolytic Systems

6.1 Primary Hemostasis, Platelet Receptors & Qualitative Platelet Disorders 6.2 Quantitative Platelet Disorders & Immune Thrombocytopenias 6.3 The Coagulation Cascade & Cell-Based Hemostatic Model 6.4 Fibrinolytic System, Natural Anticoagulants & Thrombophilia

7 Chapter 7: Factor Deficiencies, Coagulation Testing & Anticoagulation

7.1 Hereditary Coagulation Factor Deficiencies & von Willebrand Disease 7.2 Acquired Coagulation Factor Deficiencies, Circulating Inhibitors & DIC 7.3 Routine and Specialized Coagulation Testing & Mixing Study Interpretation 7.4 Anticoagulant Therapies, Laboratory Monitoring & Reversal Strategies 7.5 Viscoelastic Testing, Heparin Neutralization & Chromogenic Assays

8 Chapter 8: Hematology Laboratory Testing & Advanced Diagnostics

8.1 Automated Hematology Analyzers, Interference Flags & Manual Methods 8.2 Cytochemical Staining, Flow Cytometry & Molecular Diagnostics 8.3 Erythrocyte Sedimentation Rate, Hemolytic Indicators & Special Erythrocyte Studies 8.4 Cerebrospinal Fluid Analysis, Cell Counts & Cytology 8.5 Serous Effusions & Synovial Fluid Analysis

9 Chapter 9: Laboratory Operations, Quality Assessment & Safety

9.1 The Total Testing Process: Preanalytical, Analytical & Postanalytical Quality 9.2 Quality Control Statistics, Levey-Jennings Charts & Westgard Multirules 9.3 Laboratory Mathematics: Dilutions, Concentration, Molarity & Standard Curves 9.4 Method Evaluation, Diagnostic Statistics & Point-of-Care Testing 9.5 Regulatory Framework, Proficiency Testing & Competency Assessment 9.6 Laboratory Safety: Bloodborne Pathogens, Personal Protective Equipment & Chemical Hygiene 9.7 Emergency Response, Spill Management & Specimen Packaging and Transport 9.8 Hematology Instrumentation: Microscopy, Counters, Analyzers & Centrifuges

9.4 Method Evaluation, Diagnostic Statistics & Point-of-Care Testing

Key Takeaways Explain This Topic AI

Diagnostic sensitivity is TP/(TP+FN) and rules disease OUT when negative; specificity is TN/(TN+FP) and rules disease IN when positive.

Sensitivity and specificity are intrinsic to the test, but positive and negative predictive values depend on disease PREVALENCE, so a good assay used for screening produces mostly false positives.

Before reporting nonwaived results, CLIA requires verification of manufacturer claims for accuracy, precision, reportable range, and reference intervals; a laboratory-modified or laboratory-developed test must additionally ESTABLISH analytical sensitivity and specificity.

The analytical measurement range is the directly measured linear interval; the clinically reportable range extends it by validated dilution.

IQCP is a voluntary CLIA alternative for NONWAIVED testing requiring a risk assessment, a written quality control plan, and ongoing quality assessment; it never applies to waived testing and never removes proficiency testing or competency obligations.

Last updated: August 2026

Method Evaluation, Diagnostic Statistics & Point-of-Care Testing

Laboratory Operations includes two topics that are frequently confused: the analytical performance characteristics that describe how well an instrument measures, and the diagnostic statistics that describe how well a result predicts disease. Point-of-care testing is where both meet under a distinct regulatory model.

1. Diagnostic Statistics: The Two-by-Two Table

  • Disease Present Disease Absent
  • Test Positive True positive (TP) False positive (FP)
  • Test Negative False negative (FN) True negative (TN)

Measure Formula Plain Meaning

Diagnostic sensitivity T P T P + F N × 100 \dfrac{TP}{TP+FN}\times 100 TP + FN TP ​ × 100 Of those WITH disease, the proportion the test detects. A highly sensitive test rules disease out when negative.

Diagnostic specificity T N T N + F P × 100 \dfrac{TN}{TN+FP}\times 100 TN + FP TN ​ × 100 Of those WITHOUT disease, the proportion the test correctly calls negative. A highly specific test rules disease in when positive.

Positive predictive value T P T P + F P × 100 \dfrac{TP}{TP+FP}\times 100 TP + FP TP ​ × 100 Of those testing positive, the proportion that truly have disease

Negative predictive value T N T N + F N × 100 \dfrac{TN}{TN+FN}\times 100 TN + FN TN ​ × 100 Of those testing negative, the proportion that truly do not

Efficiency T P + T N Total × 100 \dfrac{TP+TN}{\text{Total}}\times 100 Total TP + TN ​ × 100 Overall proportion correctly classified

The single most tested principle: sensitivity and specificity are intrinsic to the test and do not change with the population. Predictive values depend on prevalence. The same assay used to screen a healthy population produces a much lower positive predictive value than when it is used in a symptomatic population, because most positives in a low-prevalence setting are false positives. This is why a D-dimer with 95% sensitivity is used to EXCLUDE venous thromboembolism in low-probability patients but never to confirm it.

Worked example. A flow cytometry screen for a PNH clone is run on 1,000 patients, 50 of whom truly have PNH. It detects 48 of them and calls 38 of the 950 unaffected patients positive. Sensitivity = 48/50 = 96%. Specificity = 912/950 = 96%. Positive predictive value = 48/(48+38) = 56%. Despite excellent sensitivity and specificity, fewer than 6 in 10 positives are real, because the disease is uncommon.

2. Analytical Performance Characteristics

Characteristic Definition How It Is Established

Analytical sensitivity (limit of detection) The lowest concentration reliably distinguished from zero Replicate analysis of blank and low-level material

Analytical specificity Freedom from interference by substances other than the analyte Interference studies with hemolysate, bilirubin, lipid, drugs

Precision Reproducibility, expressed as within-run and between-run CV Repeated measurement of controls over at least 20 days

Accuracy / bias Agreement with a reference method or reference material Method comparison against a comparative method, regression analysis

Linearity and analytical measurement range The interval over which results are directly proportional to concentration Dilution series spanning the claimed range

Clinically reportable range The AMR extended by permitted dilution or concentration AMR multiplied by the validated dilution factor

Carryover Contamination of one specimen by the preceding one High-low-low sequence testing

Reference interval verification Confirming that a published interval applies to this population Analyzing a modest number of healthy local subjects (commonly 20) and confirming acceptable agreement

For nonwaived tests, CLIA requires the laboratory to verify manufacturer performance claims for accuracy, precision, reportable range, and reference intervals before reporting patient results. If the laboratory modifies an FDA-cleared method or develops its own, it must additionally establish analytical sensitivity, analytical specificity, and other performance characteristics.

3. Point-of-Care Testing

Point-of-care testing is performed near the patient by staff who are usually not laboratory-trained, which shifts the quality burden from the instrument to the management program.

Hematology and Coagulation Point-of-Care Devices

Device Category Typical Measurement Principle Common Pitfalls

Portable hemoglobinometer Reflectance or transmission photometry on a microcuvette Poor capillary technique, milking the finger, interstitial fluid dilution; first drop must be wiped away

Point-of-care INR meter Capillary whole blood clotting on a test strip with an electrochemical or optical endpoint Not validated for lupus anticoagulant patients or for direct oral anticoagulants; INR agreement degrades above about 4.0

Activated clotting time (ACT) Whole blood clotting after contact activation, used for high-dose heparin during bypass and catheterization Insensitive at low heparin doses; hemodilution and hypothermia prolong it

Point-of-care platelet function analyzers Shear-induced platelet adhesion or aggregation on a cartridge Dependent on platelet count and hematocrit; low values in thrombocytopenia or anemia are not necessarily drug effects

Handheld blood gas and electrolyte cartridges Micro-electrode arrays Cartridge storage temperature and air bubbles

Regulatory Model

CLIA complexity. Waived tests carry the lowest regulatory burden but still require adherence to manufacturer instructions and a CLIA certificate of waiver. Moderate and high complexity point-of-care tests carry the same personnel, quality control, proficiency testing, and competency obligations as the main laboratory.

Individualized Quality Control Plan (IQCP). An optional CLIA-recognized alternative for nonwaived testing that permits a reduced control frequency only after a documented risk assessment covering specimen, environment, reagent, testing personnel, and test system, plus a written quality control plan and ongoing quality assessment. IQCP does not apply to waived testing.

Program requirements include a designated point-of-care coordinator, documented operator training and competency, lot-to-lot verification, connectivity so results reach the permanent record, and correlation studies between point-of-care devices and the central laboratory whenever both report the same analyte.